Longevity & Cellular Repair
Route(s)
Subcutaneous
Typical dose
250 mcg
Dosing window
Anytime
Receptor / target
FoxO4; p53
Properties
Not listed
Pre-mixed
No
FOXO4-DRI
← Back to Library
Protocol not independently verified Longevity Senolytic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
FOXO4-DRI is reviewed here for cellular repair and longevity research.
Research Summary
Evidence Strength
Limited
Primary Evidence
Published literature searches and source-listed protocols
Research Focus
Cellular repair, Longevity research
Mechanism
Target context: FoxO4; p53
Long-Term Data
Limited or not established.
Current Consensus
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
250 mcg
Dosing window
Anytime
Receptor / target
FoxO4; p53
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 250 mcg | Initiation phase. |
| Weeks 5-8 | 375 mcg | Escalation phase. |
| Weeks 9-12 | 500 mcg | Advanced phase. |
| Weeks 13-16 | 500 mcg | Maintenance limit. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Protocol logic check
Protocol context: Longevity protocols are where mechanistic claims most often outrun outcomes. The logic is conservative cycles, biomarkers when possible, and special caution around cancer, telomerase, senescence, and proliferative signaling. Entry context: target (FoxO4; p53); route Subcutaneous; timing Anytime. Unapproved or unverified dosing examples are hypotheses, not recommendations.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in cellular repair, mitochondrial function, senescence, telomere, NAD, oxidative-stress, and aging-model literature. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: FoxO4; p53. Route(s): Subcutaneous. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Longevity compounds often use biomarkers such as mitochondrial function, NAD metabolism, telomere signaling, senescence, inflammation, or oxidative stress rather than direct lifespan outcomes.
- Mechanistic plausibility is not the same as human clinical benefit; cancer biology and long-term safety are recurring evidence gaps.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 250 mcg.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor metabolic labs, mitochondrial or fatigue endpoints, cancer history, renal/hepatic context, and overstimulation or sleep changes.
Selected medical sources
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active malignancy or history of cancer: FOXO4-DRI disrupts the FOXO4-p53 survival interaction that senescent cells depend on; however, many cancer cells also exploit FOXO4-mediated p53 sequestration as a pro-survival mechanism; in the oncological context, uncontrolled p53 nuclear re-entry in tumor cells without clinical supervision could produce unpredictable outcomes; use in active cancer subjects requires oncological evaluation.
- Pregnancy: the pro-apoptotic cellular clearance mechanism of FOXO4-DRI has not been evaluated in the context of pregnancy; placental trophoblast cells and fetal cells share some characteristics with senescent cells and the developmental safety profile is entirely uncharacterized.
- Active systemic immunosuppression (organ transplant recipients, high-dose corticosteroid therapy, chemotherapy-induced immunosuppression): the clearance of senescent cells generates a transient acute inflammatory response as cleared cell debris is processed by the immune system; in immunosuppressed subjects this response may be dysregulated.
- Severe autoimmune disease in active flare: the acute inflammatory pulse from senescent cell clearance could worsen an already hyperactivated autoimmune inflammatory state.
- Severe hepatic or renal impairment: the cellular clearance and metabolic demands of FOXO4-DRI-induced apoptosis place additional burden on hepatic and renal clearance pathways; safety in severe organ impairment is uncharacterized.
- Known hypersensitivity to FOXO4-DRI, D-amino acid retro-inverso peptides, or formulation excipients.
- Subjects under age 25: the cellular senescence burden in young subjects is negligible; senolytic activity in tissue with a low senescent cell fraction has no meaningful therapeutic target and could theoretically disrupt progenitor cell populations that express stress-related FOXO4 activity transiently.
- Concurrent use of other senolytics (dasatinib, quercetin, navitoclax): additive senolytic activity may produce excessive simultaneous senescent cell clearance, overwhelming the immune system's capacity to process cleared debris and producing severe SASP-related inflammatory responses.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Lethargy and fatigue during cellular clearance: the most consistently reported adverse effect; as large numbers of senescent cells undergo apoptosis, the immune system mobilizes to clear the cellular debris; the metabolic demand and the transient SASP cytokine release during clearance produce a flu-like fatigue state; duration correlates with the senescent cell burden being cleared.
- Joint aches and musculoskeletal discomfort: senescent cells are disproportionately abundant in joint-adjacent tissues (cartilage, synovium, periarticular fat); their clearance produces a transient local inflammatory response characterized by joint stiffness and aching; typically self-limiting as inflammation resolves post-clearance.
- Transient acute inflammatory pulse: as senescent cells die and SASP factors are abruptly released from clearing cells, serum inflammatory markers (CRP, IL-6) transiently elevate before falling to below-baseline levels as the senescent cell burden decreases; the net long-term effect is anti-inflammatory but the acute clearance phase may be transiently pro-inflammatory.
- Mild headache: uncommon; possibly related to the systemic inflammatory response during cellular clearance.
- Injection site reactions: mild redness and soreness at the subcutaneous administration site; standard for peptide injection.
- Transient liver enzyme elevation: liver contains a high density of senescent hepatic stellate cells and hepatocytes; FOXO4-DRI-driven clearance in liver tissue may transiently elevate ALT/AST as hepatocyte turnover occurs; typically resolves within 2-4 weeks.
- Skin changes: some subjects report changes in skin texture, tone, or mild hair regrowth consistent with the de Keizer mouse data showing fur regrowth; these are the desired senolytic tissue restoration effects rather than adverse events.
- Unknown long-term safety profile: the human clinical evidence base for FOXO4-DRI is entirely preclinical; the full long-term safety spectrum in humans is not established; all use is strictly research-context with this caveat acknowledged.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.